Widgetized Section

Go to Admin » Appearance » Widgets » and move Gabfire Widget: Social into that MastheadOverlay zone

Trovagene and Nerviano Announce License Agreement for therapeutic candidate PCM-075

Published Wednesday March 15

…including Genentech (Roche), Pfizer, Array Pharmaceuticals and Servier, as well as with…

SAN DIEGO and NERVIANO, Italy, March 15, 2017 /PRNewswire/ — Trovagene, Inc.

…grants Trovagene exclusive global development and commercialization rights to NMS-1286937, which Trovagene refers to as PCM-075. PCM-075 is an oral, investigative drug and a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine polo-like-kinase 1 .

Article length: About 1040 words.
Tags: Patent Transactions Sale
Read more at Prnewswire